ALFA Finder| Revenue growth | 21% YoY to ₹1,180 Cr; underlying 12–13% ex low-base, GST. |
|---|---|
| Margins | EBITDA margin steady at 34%; gross margin down ~120 bps. |
| Demand visibility | Market grew ~14%; volume growth returned; Blenrep launch in December quarter. |
| Management confidence | Confident; margin and pricing questions answered qualitatively. |
Growth
Underlying growth 12–13% ex low-base/GST; gen-medicine volume growth 5–7%. PAT +33%, but ex-₹42 Cr refund-interest one-off ~21%.
Outlook
Targets doubling business by FY31 (~₹8,000 Cr aspiration); ~13% blended growth over five years. No next-year numeric guidance.
Risks
Margin questions deflected to 'maintain profile'; oil-linked input inflation may persist several quarters. Oncology pricing scrutiny dismissed without numbers.
Last quarter's promises, checked
Delivered
- Guided sustainable 9–10% comparable growth → underlying 12–13% ex low-base/GST (= BEAT)
- Guided EBITDA margin 'roughly 34% range' → held near 34% (= BEAT)
- Guided S&A ratio to normalise from elevated Q1 levels → spend ratio improved ~1 pp (= BEAT)
Partly delivered
- Guided established-business growth 8–10% → gen-med volume growth 5–7%; value growth not disclosed (= PARTIAL)
- Guided Bepirovirsen (Hibsago) India launch 'within three quarters latest' → only approval sought, not granted (= PARTIAL, open)
Missed
- Guided input costs not hitting 'immediate here and now' → gross margin down ~120 bps; oil-linked inflation may persist several quarters (= MISS)
- Guided Blenrep launch 'in next eight weeks latest' (Q2 or Q3) → launch slipped to December quarter (= MISS)
Earnings Call Transcript filed with NSE, NSE: GLAXO. Summary written with AI assistance from the document.
GlaxoSmithKline Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,524.80
- Market cap
- ₹42,772 Cr
- Revenue (annual)
- ₹3,822 Cr
- Net profit (annual)
- ₹1,036 Cr
- P/E (TTM)
- 37.3×Sector 43.0×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 4.75%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from GlaxoSmithKline Pharmaceuticals Ltd
All →GlaxoSmithKline Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 standalone revenue ₹1,180cr (+21%), EBITDA ₹400cr (34% margin), PAT ₹335cr (+33%). Innovation portfolio now 7% of sales, driving portfolio transformation.
GlaxoSmithKline Pharmaceuticals Management Change
GlaxoSmithKline Pharmaceuticals appointed Sandeep Seth as Head - Ethics & Compliance, effective 3 November 2026. He brings over 20 years of compliance and governance experience.
GlaxoSmithKline Pharmaceuticals Other Announcement
GSK Pharmaceuticals appointed M/s. Walker Chandiok & Co. LLP as Statutory Auditor, effective 1 April 2027 for a 60-month term. The appointment was approved at the board meeting held on 3 November 2026.
- Execution
- 1 April 2027 for 60 months
GlaxoSmithKline Pharmaceuticals Results Update
GSK Pharmaceuticals reported Q2 FY27 media release showing revenue of INR 1180 crore (up 21%) and PAT of INR 335 crore (up 31%). The release also announces the upcoming BLENREP launch in India.
GlaxoSmithKline Pharmaceuticals Q2 FY27 Results: Net Profit ₹335.9 Cr, Up 30.4% YoY
GlaxoSmithKline Pharmaceuticals Ltd reported revenue from operations of ₹1,184 Cr (+20.8% YoY) and net profit of ₹335.9 Cr (+30.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹335.9 Cr · +30.4% YoY
GlaxoSmithKline Pharmaceuticals Board Meeting Date
GlaxoSmithKline Pharmaceuticals Limited will hold a board meeting on 3rd November 2026 to consider and approve its unaudited financial results for the quarter ended 30th September 2026.